UBS Group’s Endologix Inc ELGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-20,000
| Closed | -$16K | – | 8840 |
|
|
2020
Q2 | $16K | Buy |
+20,000
| New | +$16.9K | ﹤0.01% | 6720 |
|
|
2019
Q1 | – | Sell |
-7,227
| Closed | -$52K | – | 8536 |
|
|
2018
Q4 | $52K | Buy |
7,227
+6,040
| +509% | +$67.3K | ﹤0.01% | 6065 |
|
|
2018
Q3 | $22K | Sell |
1,187
-476
| -29% | -$17K | ﹤0.01% | 6763 |
|
|
2018
Q2 | $94K | Buy |
1,663
+1,601
| +2,582% | +$81.2K | ﹤0.01% | 5492 |
|
|
2018
Q1 | $3K | Sell |
62
-354
| -85% | -$15.2K | ﹤0.01% | 7487 |
|
|
2017
Q4 | $23K | Buy |
416
+117
| +39% | +$6.18K | ﹤0.01% | 6463 |
|
|
2017
Q3 | $13K | Sell |
299
-41
| -12% | -$1.87K | ﹤0.01% | 6751 |
|
|
2017
Q2 | $16K | Sell |
340
-499
| -59% | -$29.4K | ﹤0.01% | 6477 |
|
|
2017
Q1 | $61K | Buy |
839
+829
| +8,290% | +$54.8K | ﹤0.01% | 5380 |
|
|
2016
Q4 | $1K | Sell |
10
-280
| -97% | -$25.6K | ﹤0.01% | 7681 |
|
|
2016
Q3 | $37K | Sell |
290
-815
| -74% | -$104K | ﹤0.01% | 5762 |
|
|
2016
Q2 | $137K | Buy |
1,105
+317
| +40% | +$36.4K | ﹤0.01% | 4817 |
|
|
2016
Q1 | $66K | Buy |
788
+251
| +47% | +$20.7K | ﹤0.01% | 5284 |
|
|
2015
Q4 | $54K | Sell |
537
-13
| -2% | -$1.39K | ﹤0.01% | 5754 |
|
|
2015
Q3 | $67K | Sell |
550
-289
| -34% | -$39.2K | ﹤0.01% | 5564 |
|
|
2015
Q2 | $128K | Buy |
839
+349
| +71% | +$57.6K | ﹤0.01% | 5222 |
|
|
2015
Q1 | $84K | Sell |
490
-278
| -36% | -$42.1K | ﹤0.01% | 5566 |
|
|
2014
Q4 | $117K | Buy |
+768
| New | +$95.9K | ﹤0.01% | 5539 |
|
Other funds holding ELGX
UBS Group's ELGX Position: Q3 2020 in Review
UBS Group sold out of Endologix Inc (ELGX) in Q3 2020, closing a stake of 20,000 shares — an estimated $16K sold.
UBS Group first reported a position in ELGX in Q4 2014 and held it in 18 quarters. The position peaked at $137K in Q2 2016. 6 funds tracked by Wall St. Rank hold ELGX as of Q3 2020.
- UBS Group reported no remaining Endologix Inc position as of Q3 2020 after selling out during the quarter.
- UBS Group sold 20,000 Endologix Inc shares in Q3 2020, an estimated $16K.
- UBS Group first reported a position in Endologix Inc in Q4 2014 and held it in 18 quarters.
- UBS Group's Endologix Inc position peaked at $137K in Q2 2016.
- 6 funds tracked by Wall St. Rank held Endologix Inc as of Q3 2020.
Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.